Audit experiences in investigational medicinal product management and errors in clinical trials
Abstract Background Clinical audits are essential to ensure that clinical research processes align with regulatory standards and best practices. Despite this, there has been no error assessment of the relationship between the errors in investigational medicinal product (IMP) management and clinical...
Saved in:
| Main Authors: | Yunjeong Kim, Heeyoung Lee |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-03-01
|
| Series: | Trials |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13063-025-08795-w |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Experience and lessons learned relating to investigational product supply in the design and delivery of a paediatric investigator-initiated clinical trial
by: Mandy Wan, et al.
Published: (2025-08-01) -
Regulation and status of herbal medicine clinical trials in Korea
by: Boram Lee, et al.
Published: (2021-06-01) -
Inclusion of under-served groups in trials: an audit at a UK primary care clinical trials unit
by: Rebekah Burrow, et al.
Published: (2025-06-01) -
Investigator Initiated Trials: modern trends
by: A. G. Torubarova, et al.
Published: (2019-01-01) -
Study on knowledge, practices, and attitudes toward decentralized clinical trials among the clinical trial practitioners in China
by: Yuanyuan Shi, et al.
Published: (2025-04-01)